It is concluded that the high expression of FGF2, FGFR3, and FGFBP1 in patients with ESCC may be prone to be resistant to chemotherapeutic drugs or radiotherapy. This evidence concerns the gene FGFBP1 and esophageal squamous cell carcinoma.